Tracer library / [90Y]Y-L4-Lipo/
[90Y]Y-L4-Lipo/
Also written as [Y-90]Y-L4-Lipo/
- Radionuclide
- Y-90 t½ 3843.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- Preclinical
- Syntheses indexed
- 3
What it is
- Compound class
- Lipiodol-based lipophilic ligand formulation (ethyl esters of iodized fatty acids of poppy seed oil complexed with a lipophilic chelating ligand)
- Target / mechanism
- —
- Clinical application
- Transarterial radioembolization (TARE) for selective arterial delivery of localized radiation to advanced unresectable liver tumors, including hepatocellular carcinoma PMID 40493323
- Theranostic pair
- —
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Neptis Mosaic-LC ORA | vendor cassette | — | 56.21 ± 18.04% | 91.64 ± 5.75% | L4-Lipo ligand Guerbet Research and Innovation department, Aulnay-sous-Bois, France | 40493323 2025 EJNMMI Radiopharm Chem we set-up an automated procedure with single-use disposable cassettes for the preparation of [90Y]Y-L4-Lipo/Lipiodol®, using a Neptis LC module - the radiotracer was obtained with a final yield of 56.21 ± 18.04%, and an RCP of 91.64 ± 5.75% (n = 9) |
| Manual synthesis | — | — | 95.48 ± 6.72% | 96.25 ± 3.30% | L4-Lipo ligand Guerbet Research and Innovation department, Aulnay-sous-Bois, France | 40493323 2025 EJNMMI Radiopharm Chem A 0.5 mL amount of an [90Y]YCl3 solution was diluted in various 1 M acetate buffers (pH = 3.5, 4.65, 5.2, 7 and 9), purified on Chelex resin, and filtered. - [90Y]Y-L4-Lipo was obtained with a radiochemical yield (RCY) of 95.48 ± 6.72%, as determined by thin-layer chromatography |
| Manual synthesis | — | — | 93.07 ± 4.36% | 92.59 ± 7.33% | L4-Lipo ligand Guerbet Research and Innovation department, Aulnay-sous-Bois, France | 40493323 2025 EJNMMI Radiopharm Chem 90Y/111In-radiocomplexes prepared under optimized reaction conditions were extracted into Lipiodol® Ultra-Fluid. - [90Y]Y-L4-Lipo/Lipiodol® Ultra-Fluid was obtained with an extraction yield of 93.07 ± 4.36%, and the RCP of the final product was 92.59 ± 7.33% |
Precursor
- Common precursor
- —
- Suppliers seen in the literature
- —
- Cited suppliers in indexed syntheses
- Guerbet Research and Innovation department
- Typical final purification
- —
Need this precursor?We can point you to suppliers for [90Y]Y-L4-Lipo/, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40493323. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 39 from PMID 40493323: 'investigate its biodistribution in an animal model, and conduct an initial dosimetry evaluation'.